Skip to main content
main-content

01.12.2013 | Letter to the Editor | Ausgabe 1/2013 Open Access

Journal of Hematology & Oncology 1/2013

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome

Zeitschrift:
Journal of Hematology & Oncology > Ausgabe 1/2013
Autoren:
Jana Štikarová, Jiří Suttnar, Kristýna Pimková, Leona Chrastinová-Mášová, Jaroslav Čermák, Jan E Dyr
Wichtige Hinweise

Competing interest

The authors indicated no potential conflicts of interest.

Authors’ contributions

JŠ performed LC-MS/MS analysis of methylated derivatives of arginine. JS participated on LC-MS/MS analysis of methylated derivatives of arginine, carried out data analysis and interpretation and wrote the manuscript. KP and LCM performed malondialdehyde and nitrite analysis. JČ provided clinical data and patient samples. JED conceived of the study and wrote the manuscript. Final approval of the manuscript: All the co-authors. All authors read and approved the final manuscript.
Abbreviations
MDS
Myelodysplastic syndromes
NOS
Nitric oxide synthase
ADMA
NG,NG-dimethyl-L-arginine
MMA
NG-monomethyl-L-arginine
SDMA
NG,NG’-dimethyl-L-arginine
MDA
Malondialdehyde
PRMT
protein arginine methyltransferase.

To the editor

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders, characterized by ineffective hematopoiesis and a high risk of transformation into acute myeloid leukemia. It has been determined that oxidative stress plays a role in the initialization and disease progression [1]. The reactive oxygen species may oxidize tetrahydrobiopterin resulting into nitric oxide synthase (NOS) uncoupling and preferential formation to superoxide anion radical. It was found that methylarginines (asymmetric dimethylarginine - ADMA, NG-monomethyl-L-arginine - MMA and symmetric dimethylarginine - SDMA), naturally occurring inhibitors of NOS [2], can profoundly increase superoxide generation from uncoupled NOS [3]. Free methylated arginines, capable of inhibiting NOS [4], are formed exclusively by the sequence of methylation of arginine residues of proteins, followed by proteolysis of these proteins. Protein arginine methylation is in mammalian cells carried out by protein arginine methyltransferases (PRMTs); many of them show links to cancer [5].
The subjects of the study are characterized in Table 1. Ethics approval (Ethics Committee of the Institute of Hematology and Blood Transfusion) and informed consent from all subjects were obtained. Serum concentration of oxidative stress marker malondialdehyde (MDA) was estimated using liquid chromatography (Shimadzu, Tokyo, Japan) of its thiobarbituric acid derivative [6]. Methylated arginines were analyzed using HILIC chromatography with MS/MS detection (ABSciex, Framingham, USA) [7]. Nitrites were assayed by chromatography using the fluorescent reaction product with 2,3-diaminonaphthalene [8].
Table 1
Baseline characteristics of MDS patients and healthy controls
 
MDS
Controls
aAge (years)
43.7 (33–59)
44.3 (37–67)
Male/Female
11/9
8/8
aSerum iron [μmol/L]
22.3 (11.4-43.3)
b8.5-28
aSerum ferritin [μg/L]
641.2 (8.9-1907.3)
b15-150
aThe data are depicted as averages with ranges. bReference interval.
The concentrations of methylated arginine derivatives, malondialdehyde and nitrites are summarized in the Table 2. We found significantly increased serum concentrations of ADMA, SDMA, MMA, and MDA in sera of MDS patients as compared with healthy donors. The nitrites concentrations were significantly decreased in sera of MDS patients as compared with controls. The concentration of ADMA strongly positively correlated with concentration of MMA (r = 0.87, p < 0.001) and SDMA (r = 0.70, p < 0.001). ADMA concentration moderately positively correlated with MDA concentration (r = 0.50, p = 0.006).
Table 2
Concentrations of methylated arginines in sera of MDS patients and healthy controls
 
MDS
Controls
ap
ADMA [μmol/L]
0.84 ± 0.32
0.56 ± 0.16
0.0022**
SDMA [μmol/L]
0.54 ± 0.18
0.42 ± 0.14
0.0361*
MMA [μmol/L]
0.14 ± 0.05
0.10 ± 0.03
0.033*
Homoarginine [μmol/L]
1.77 ± 1.06
2.32 ± 1.26
0.1777
Citrulline [μmol/L]
46.68 ± 14.96
42.19 ± 12.31
0.3298
MDA [μmol/L]
0.77 ± 0.11
0.52 ± 0.07
<0.001***
Nitrites [μmol/L]
1.71 ± 0.46
2.16 ± 0.38
0.0028**
The data are represented as averages ± SD. ADMA, NG, NG-dimethyl-L-arginine; MMA, NG-monomethyl-L-arginine; SDMA, NG,NG’-dimethyl-L-arginine; MDA, malondialdehyde. aTwo-tailed t-test was used to compare measured concentrations of analytes in MDS patients with healthy donors. Statistical significance coding: * p < 0.05, ** p < 0.01 and *** p < 0.001.
Our results showed significantly increased oxidative stress even in MDS patients characterized by moderately enhanced iron and serum transferrin concentrations. Resulting shift of overexpressed [9] NO synthase activity in favour of superoxide production at the expense of nitric oxide synthesis (reflected by nitrites concentrations [10]) was further augmented at the presence of methylated arginines. Therefore, oxidative stress in MDS patients could be explained by a positive feedback of both superoxide and methylated arginines on original NOS activity impairment. Moreover, recently proposed PRMT-specific inhibitors [11] might have a therapeutic effect on leukemia also by oxidative stress reduction.

Acknowledgement

This work was supported by Grant CZ.2.16/3.1.00/24001 of the EU ERDF OPPK, by P205/12/G118 of Centrum Excellence, by Grant KAN200670701 from the Academy of Sciences, Czech Republic and by the Ministry of Health, Czech Republic project for the conceptual development of research organization, VZ MZ 00002373601 IHBT.

Competing interest

The authors indicated no potential conflicts of interest.

Authors’ contributions

JŠ performed LC-MS/MS analysis of methylated derivatives of arginine. JS participated on LC-MS/MS analysis of methylated derivatives of arginine, carried out data analysis and interpretation and wrote the manuscript. KP and LCM performed malondialdehyde and nitrite analysis. JČ provided clinical data and patient samples. JED conceived of the study and wrote the manuscript. Final approval of the manuscript: All the co-authors. All authors read and approved the final manuscript.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2013

Journal of Hematology & Oncology 1/2013 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise